Glecirasib could also potently inhibit cell viability of KRAS p.G12C–carrying cancer cell lines, such as NCI-H1373, NCI-H385, and MIA PaCa-2, with a low median IC50 value of 11.8 nmol/L (n = 7). This evidence concerns the gene KRAS and cancer.